Luye Pharma Group Ltd (2186.HK)
23 Apr 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|51||2016||Executive Chairman of the Board, Chief Executive Officer|
|51||2015||Vice Executive Chairman of the Board|
|53||2012||Chief Financial Officer|
|55||2014||Senior Vice President, Head of R&D|
|53||2014||Senior Vice President, General Manager of Shandong Luye|
- BRIEF-Luye Pharma Group Says LY03003 Drug Approved To Proceed To Phase III Clinical Trials In China
- BRIEF-Luye Pharma Group Posts FY Profit Attributable Of RMB981.4 Million
- BRIEF-Luye Pharma Group Announces collaboration With Excel Biopharma
- BRIEF-Luye Pharma Group Says Rotigotine Exempted From Phase 2 Dosage Exploration Clinical Trials
- BRIEF-Luye Pharma Group Says CFDA Accepted Clinical Trial Application For Co's Anti-Tumor Drug